Strict glycaemic control in diabetic patients with CKD or ESRD: Beneficial or deadly?

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2044-2047

  Schernthaner, Guntram ^a   Ritz, Eberhard ^b   Schernthaner, Gerit Holger ^c  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ERYTHROPOIETIN; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; SURVIVAL; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; METABOLISM; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

BLOOD GLUCOSE; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SURVIVAL RATE;

EID: 77954340252     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq199     Document Type: Note

References (48)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
3. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
4. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
5. Morath C, Zeier M, Dohler B et al. Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol 2008; 19: 1557-1563
6. Wiesbauer F, Heinze G, Regele H et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation 2010; 89: 612-619
7. Schneider CA, Ferrannini E, Defronzo R et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19: 182-187
8. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009; 63: 912-929
9. USRDS. USRDS 2008 Annual Data Report 2008
10. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913
11. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500
12. Hayashino Y, Fukuhara S, Akiba T et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007; 50: 1170-1177 (Pubitemid 46701557)
13. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055
14. Drechsler C, Krane V, Ritz E et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009; 120: 2421-2428
15. Williams ME, Lacson E Jr., Teng M et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509
16. Schernthaner G, Stummvoll KH, Muller MM. Glycosylated haemoglobin in chronic renal failure. Lancet 1979; 1: 774
17. Inaba M, Okuno S, Kumeda Y et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903
18. Peacock TP, Shihabi ZK, Bleyer AJ et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemo-dialysis. Kidney Int 2008; 73: 1062-1068
19. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52 17-30
20. Schernthaner G, Barnett AH, Betteridge J. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? a critical analysis. Diabetologia 2010, doi: 10.1007/s00125-010-1702-3
21. Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 2009; 24: 338-341
22. Holstein A, Plaschke A, Hammer C et al. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003; 59: 91-97
23. Tsoulaki I, Molokhia M, Curcin V. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Brit Med J 2010 Dec 3; 339: b4731. doi: 10.1136/bmj.b4731
24. Brunelli SM, Thadhani R, Ikizler TA et al. Thiazolidine-dione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009; 75: 961-968
25. Ramirez SP, Albert JM, Blayney MJ et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20: 1094-1101
26. c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489
27. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
28. Haag-Weber M, Kramer R, Islam M et al. Low GDP fluid (Gambrosol trio R) attenuates decline of residual renal function in PD patients. Nephrol Dial Transplant 2010; In press
29. Lee HY, Choi HY, Park HC et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899
30. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
31. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94
32. Kim S, Oh J, Kim S et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24: 2899-2908
33. Weiss L, Stegmayr B, Malmsten G et al. Biocompatibility and toler-ability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29: 647-655
34. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution\clinical benefits. Perit Dial Int 2000; 20: 516-523
35. Le Poole CY, Welten AG, Weijmer MC et al. Initiating CAPD with a regimen low in glucose and glucose degradation products, with ico-dextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25: S64-S68
36. Szeto CC, Chow KM, Lam CWK et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products\a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559
37. Choi HY, Kim DK, Lee TH et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Pe r i t Dial Int 2008; 28: 174-182
38. Fan SLS, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2007; 73: 200-206
39. Fang W, Mullan R, Shah H et al. Comparison between bicarbonate/lactate and standard lactate solution in peritoneal transport and ultra-filtration: a prospective, crossover, single-dwell study. Perit Dial Int 2008; 28: 35-43
40. Bargman JM. Peritoneal dialysis solutions and patient survival: does wishing make it so? Nephrol Dial Transplant 2006; 21: 2684-2686
41. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009; 24: 2620-2622
42. Friedlander MA, Wu YC, Schulak JA et al. Influence of dialysis modality on tissue and fluid concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445-451
43. Ateshkadi A, Johnson CA, Founds HWet al. Serum advanced glyca-tion end-products in patients on hemodialysis and CAPD. Perit Dial Int 1995; 15: 129-133
44. Gerdemann A, Wagner Z, Solf A et al. Plasma levels of advanced glycation endproducts during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17: 1045-1049
45. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305
46. Muller-Krebs S, Kihm LP, Zeier B et al. Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 2008; 38: 296-305
47. Erixon M, Wieslander A, Linden T et al. 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma. Perit Dial Int 2009; S28-S31
48. Received for publication: 25.3.10; Accepted in revised form: 26.3.10